The fact that there's no benefit-cost analysis: I'll be raising this in the committee of the whole House with the Minister, but I would encourage the select committee, in taking advice from Pfizer, to actually do it by way of an inquiry and I trust Mr Utikere, with his Labour colleagues, to consider that very carefully. I think two things would be considered in such an inquiry that we could hold in the spring or early summer, and that is: what is the evidence of benefit for the fourth dose, or the second booster, and what was the cost of administering 830,000 doses of that fourth dose, and was that matched by, as the regulatory impact statement (RIS) said, the number of avoidable hospital admissions, harm, and death—because I think the RIS has a much stronger sense of the benefit here than the World Health Organization did in its article last month. 